Current therapeutic approaches for SMA involve antisense oligonucleotides (ASOs) targeting RNA splicing of the SMN2 gene, leading to an increase in full-length mRNA levels and subsequently enhancing the production of functional SMN4. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.